BioCentury | Aug 31, 2017
Finance

Fund fine-tuning

...€250 million ($323 million); and the Roche (SIX:ROG; OTCQX:RHHBY) takeout of cancer and autoimmune company Glycart Biotechnology AG...
BioCentury | Feb 16, 2015
Clinical News

Gazyva obinutuzumab: Phase III data

...Roche gained Gazyva, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Feb 2, 2015
Clinical News

Gazyva obinutuzumab: Phase Ib data

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Feb 2, 2015
Clinical News

Gazyva obinutuzumab: Phase Ib data

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Oct 6, 2014
Clinical News

Gazyva regulatory update

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Aug 11, 2014
Clinical News

Gazyva regulatory update

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Aug 4, 2014
Clinical News

Gazyvaro regulatory update

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | May 26, 2014
Clinical News

Gazyva regulatory update

...mAb against CD20, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Nov 11, 2013
Clinical News

Gazyva obinutuzumab: Additional Phase III data

...gained the product, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Nov 8, 2013
Clinical News

Gazyva vs. rituximab PFS numbers unveiled

...a humanized mAb against CD20 developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
Items per page:
1 - 10 of 56
BioCentury | Aug 31, 2017
Finance

Fund fine-tuning

...€250 million ($323 million); and the Roche (SIX:ROG; OTCQX:RHHBY) takeout of cancer and autoimmune company Glycart Biotechnology AG...
BioCentury | Feb 16, 2015
Clinical News

Gazyva obinutuzumab: Phase III data

...Roche gained Gazyva, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Feb 2, 2015
Clinical News

Gazyva obinutuzumab: Phase Ib data

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Feb 2, 2015
Clinical News

Gazyva obinutuzumab: Phase Ib data

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Oct 6, 2014
Clinical News

Gazyva regulatory update

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Aug 11, 2014
Clinical News

Gazyva regulatory update

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Aug 4, 2014
Clinical News

Gazyvaro regulatory update

...Roche gained obinutuzumab, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | May 26, 2014
Clinical News

Gazyva regulatory update

...mAb against CD20, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Nov 11, 2013
Clinical News

Gazyva obinutuzumab: Additional Phase III data

...gained the product, which was developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
BioCentury | Nov 8, 2013
Clinical News

Gazyva vs. rituximab PFS numbers unveiled

...a humanized mAb against CD20 developed using GlycoMAb glycosylation technology, through its 2005 acquisition of Glycart Biotechnology AG...
Items per page:
1 - 10 of 56